Three Breakthrough Treatments Could Transform Eye Health in 2025-2026

Three groundbreaking eye treatments are moving closer to reality, with one receiving FDA breakthrough status and two others showing remarkable results in clinical trials. These developments could dramatically change how doctors treat some of the most challenging eye conditions, from thyroid-related vision problems to age-related macular degeneration.

What Makes the Thyroid Eye Disease Treatment So Promising?

The Food and Drug Administration granted breakthrough therapy designation to veligrotug, an investigational drug for thyroid eye disease (TED). This rare condition causes the muscles and tissues around the eyes to swell, leading to bulging eyes and double vision. The designation was awarded based on the drug's "consistent and robust improvement and resolution of diplopia in chronic TED, and rapid onset of proptosis response."

Viridian Therapeutics completed two Phase 3 clinical trials that represent the largest pivotal program for thyroid eye disease to date. In both studies, veligrotug met its primary and secondary goals while being generally well-tolerated by patients. The company plans to submit their application to the FDA in the second half of 2025, with a potential U.S. launch in 2026 if approved.

How Does the New Dry Macular Degeneration Drug Work?

Cognition Therapeutics announced positive Phase 2 results for zervimesine (CT1812), an oral medication that could protect retinal cells from damage caused by dry age-related macular degeneration (AMD). The drug works by binding to a sigma-2 receptor found on retina and brain cells, which helps regulate how retinal cells process low-density lipoprotein—a process that becomes damaged in dry AMD.

In a proof-of-concept trial involving 100 people with geographic atrophy secondary to dry AMD, participants treated with zervimesine showed impressive results. The treatment group experienced a 28.6% slower growth rate of geographic atrophy lesions compared to those receiving placebo. Overall, the geographic atrophy lesion area was reduced by 28.2% over 18 months in the treatment group.

What About Chronic Eye Pain Relief?

EyeCool Therapeutics reported positive results from a double-masked, randomized pilot study of 31 patients testing their investigational device (ETX-4143) for chronic ocular surface pain. The device is designed to cool the eye surface for four minutes, targeting the myelinated long ciliary nerves responsible for pain sensation.

The study showed significant reduction in patient-reported eye surface pain. According to the company, the nerves regenerate myelin in the months following treatment, which may require retreatment over time. The company plans to begin a U.S. pivotal trial after receiving FDA approval for an investigational device exemption.

These breakthrough treatments address three distinct but serious eye conditions:

• Thyroid Eye Disease: Veligrotug targets the swelling and muscle problems that cause bulging eyes and double vision in people with thyroid disorders
• Dry Macular Degeneration: Zervimesine protects retinal cells from the waste product buildup that leads to central vision loss in older adults
• Chronic Eye Pain: ETX-4143 uses targeted cooling to interrupt pain signals from damaged eye surface nerves

Additional research from the Karolinska Institute revealed that certain B vitamins (B6, B9, B12, and choline) may offer neuroprotective effects in glaucoma. In animal studies, mice with slower-developing glaucoma that received these supplements showed halted optic nerve damage, while rats with more progressive glaucoma experienced slowed progression—even without lowering eye pressure. A clinical trial using this vitamin supplementation in humans has begun in Sweden.